239 related articles for article (PubMed ID: 25560237)
21. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
Sharma C; Dey B; Wahiduzzaman M; Singh N
Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
24. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
26. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.
Hibbitts S
Curr Opin Mol Ther; 2010 Oct; 12(5):598-606. PubMed ID: 20886392
[TBL] [Abstract][Full Text] [Related]
27. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein.
Liu H; Wu BH; Rowse GJ; Emtage PC
Clin Vaccine Immunol; 2007 Aug; 14(8):1013-23. PubMed ID: 17596433
[TBL] [Abstract][Full Text] [Related]
28. A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses.
Mousavi T; Valadan R; Rafiei A; Abbasi A; Haghshenas MR
Biotechnol Lett; 2021 Sep; 43(9):1933-1944. PubMed ID: 34313864
[TBL] [Abstract][Full Text] [Related]
29. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
30. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
Wieking BG; Vermeer DW; Spanos WC; Lee KM; Vermeer P; Lee WT; Xu Y; Gabitzsch ES; Balcaitis S; Balint JP; Jones FR; Lee JH
Cancer Gene Ther; 2012 Oct; 19(10):667-74. PubMed ID: 22918471
[TBL] [Abstract][Full Text] [Related]
31. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.
Oosterhuis K; Aleyd E; Vrijland K; Schumacher TN; Haanen JB
Hum Gene Ther; 2012 Dec; 23(12):1301-12. PubMed ID: 22971245
[TBL] [Abstract][Full Text] [Related]
32. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
33. Generation and characterization of a preventive and therapeutic HPV DNA vaccine.
Kim D; Gambhira R; Karanam B; Monie A; Hung CF; Roden R; Wu TC
Vaccine; 2008 Jan; 26(3):351-60. PubMed ID: 18096279
[TBL] [Abstract][Full Text] [Related]
34. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
[TBL] [Abstract][Full Text] [Related]
35. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts.
Tseng CW; Trimble C; Zeng Q; Monie A; Alvarez RD; Huh WK; Hoory T; Wang MC; Hung CF; Wu TC
Cancer Immunol Immunother; 2009 May; 58(5):737-48. PubMed ID: 18815785
[TBL] [Abstract][Full Text] [Related]
36. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.
Peng S; Qiu J; Yang A; Yang B; Jeang J; Wang JW; Chang YN; Brayton C; Roden RBS; Hung CF; Wu TC
Cell Biosci; 2016; 6():16. PubMed ID: 26918115
[TBL] [Abstract][Full Text] [Related]
37. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
Talebi S; Bolhassani A; Azad TM; Arashkia A; Modaresi MH
Protein Pept Lett; 2017; 24(3):190-196. PubMed ID: 28000571
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.
Lasaro MO; Diniz MO; Reyes-Sandoval A; Ertl HC; Ferreira LC
Microbes Infect; 2005 Dec; 7(15):1541-50. PubMed ID: 16213178
[TBL] [Abstract][Full Text] [Related]
39. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
